ExploreWatchlistsPricing
  1. JP-listed companies
  2. StemCell Institute Inc.
  3. Financials
  4. EBITDA

StemCell Institute Inc. (7096)

Market cap
¥8B
P/E ratio
24.9x
Stemcell Research Institute stores umbilical cord blood and tissue for expecting families, preserving stem cells for potential future medical treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 2025547+2.33%
Mar 31, 2024534+32.76%
Mar 31, 2023402+24.28%
Mar 31, 2022324+170.65%
Mar 31, 2021120-71.11%
Mar 31, 2020414+65.11%
Mar 31, 2019251

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat